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Abstract
Introduction Bariatric surgery is the only treatment option
that achieves sustained weight loss in obese patients and that
also has positive effects on obesity-related comorbidities.
Laparoscopic sleeve gastrectomy (LSG) seems to achieve
equal weight loss as laparoscopic Roux-en-Y gastric bypass
(LRYGB), but there is still much debate about the quality of
life (QOL) after LSG, mainly concerning the association with
gastroesophageal reflux. Our hypothesis is that QOL after
LSG is comparable with QOL after LRYGB.
Materials and Methods Between February 2013 and
February 2014, 150 patients were randomized to undergo
either LSG or LRYGB in our clinic. Differences in QOL were
compared between groups by using multiple QOL question-
naires at follow-up moments preoperatively and 2 and
12 months after surgery.
Results After 12 months of follow-up, 128 patients had
returned the questionnaires. Most QOL questionnaires
showed significant improvement in scores between the preop-
erative moment and after 12 months of follow-up. The
Gastroesophageal Reflux Disease Questionnaire (GerdQ)
score deteriorated in the LSG group after 2 months, but recov-
ered again after 12 months. After 2 months of follow-up, the
mean GerdQ score was 6.95 ± 2.14 in the LSG group versus
5.50 ± 1.49 in the LRYGB group (p < 0.001). After 1 year, the
mean GerdQ score was 6.63 ± 2.26 in the LSG group and
5.60 ± 1.07 in the LRYGB group (p = 0.001).
Conclusion This randomized controlled trial shows that pa-
tients who underwent LSG have significantly higher GerdQ
scores at both 2 and 12 months postoperatively than patients
who underwent LRYGB, whereas overall QOL did not differ
significantly.
Keywords Bariatric surgery . Sleeve . Bypass . Quality of
life . Gastroesophageal reflux disease
Introduction
The prevalence of overweight and obesity has been increasing
over the last 30 years. As of 2015, 50% of adults in the
Netherlands are overweight, with almost 14% being obese
[1]. Obesity is associated with significant morbidity, including
cardiovascular disease, type 2 diabetes mellitus (T2DM), and
mortality [2]. Another frequently seen comorbidity is gastro-
esophageal reflux disease (GERD) [3].
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Bariatric surgery is considered to be the best treatment op-
tion for patients with morbid obesity in terms of sustained
weight loss [4–6]. Not only does bariatric surgery achieve
significant excess weight loss, but it also has positive effects
on obesity-related comorbidities such as T2DM, hyperten-
sion, dyslipidemia, asthma, and sleep apnea [7–9].
The most frequently performed bariatric procedure in
Europe is laparoscopic Roux-en-Y gastric bypass
(LRYGB). It is regarded as the gold standard in bariat-
ric surgery [10, 11]. Over the past decade, laparoscopic
sleeve gastrectomy (LSG) has gained ground as a new
bariatric procedure [11]. In 2013, 37% of the performed
bariatric procedures worldwide were LSGs, compared to
28% in 2011 [11, 12].
LSG is a safe procedure that has multiple advantages. LSG
has the technical advantage that mobilization of the small
intestine is not needed. Consequently, there is also no possi-
bility of internal herniation, a risk after LRYGB. Due to the
intact pylorus muscle, there is a reduced risk of dump-
ing syndrome, and as there is no bypass of the small
intestine, we see less malabsorption syndromes in LSG
[13]. Lastly, the duodenum is still accessible for endos-
copy and interventions such as endoscopic retrograde
cholangiopancreatography (ERCP) [14–16]. LSG can al-
so be converted into LRYGB or biliopancreatic diver-
sion with duodenal switch (BPD-DS) if the treatment
fails or if complications occur.
According to a recent systematic review, the most frequent-
ly reported disadvantage is the onset of GERD after LSG, or
worsening of pre-existing GERD. The impact of this compli-
cation is controversial however, since the described studies
have reported paradoxical outcomes [17]. Several RCTs com-
paring LSG with LRYGB have been published so far, but
these studies have mostly focused on the percentage of excess
weight loss (%EWL) and less on quality of life (QOL). In
these studies, the %EWL appeared to be equal for both
LRYGB and LSG [18–26]. Prior concerns were that the
gastric sleeve would lose its effect over time, resulting
in a decline in weight loss or even weight regain, and
the need to convert to LRYGB or BPD-DS [25, 26].
Other long-term studies have disproved these concerns
however, since overall QOL appears to be similar after
LSG compared with LRYGB [27]. However, most stud-
ies have used only general QOL questionnaires and did
not focus on specific obesity-related comorbidities such
as GERD, which is one of the most important possible
complications of LSG [18, 28–31]. Therefore, the aim
of this trial is to assess short-term and medium-term
differences in QOL between LSG and LRYGB using
multiple general and obesity-related QOL question-
naires. Our hypothesis is that QOL regarding GERD
and other abdominal symptoms after LSG is comparable
with QOL after LRYGB.
Materials and Methods
Study Design
This report is based on a randomized controlled trial of pa-
tients in our center which had an indication for bariatric sur-
gery. Patients were 1:1 randomized to either LSG or LRYGB
using a randomization website. At randomization, patients
were stratified for sex, presence of T2DM, and body mass
index (BMI) >50 kg/m2.
Patient Selection
All morbidly obese patients who have been approved by the
preoperative multidisciplinary team between February 2013
and February 2014 were included in this trial. There was no
power analysis, because there were no previous data about
these questionnaires in this specific population at the time.
The inclusion criteria of this trial are identical to the IFSO
criteria for undergoing bariatric surgery [32].
Exclusion criteria were a history of GERD (defined as a
gastroscopy with symptoms of GERD, or the use of proton
pump inhibitors with symptoms of pyrosis, heartburn, or re-
gurgitation during the preoperative consultation), a symptom-
atic hiatal hernia [33], severe sweet eating [34], prior bariatric
surgery, prior major abdominal surgery, the inability to read or
understand Dutch questionnaires, a history of psychiatric and
psychological disorders, and unwillingness to be randomized
to treatment.
Treatment
LSG is performed by mobilizing the greater curvature and the
posterior wall of the stomach, after which a 34-French (Fr)
calibration tube is advanced into the antrum and used as ref-
erence. Stapling starts 4 cm proximal to the pylorus. The used
technique was described in 2012 and proven to be effective
and safe [35, 36].
LRYGB is performed with the antecolic linear technique.
A small 4-cm-long pouch is calibrated over a 34-Fr calibration
tube, and a 3-cm linear gastroenterostomy is realized. The
measured biliopancreatic limb is 60 cm, and the alimentary
limb is 150 cm. The omentum can be divided at the surgeon’s
discretion. Both mesenteric defects are closed with an endo-
scopic clipping device [35].
All participating surgeons are experienced in bariatric sur-
gery and have performed at least 150 LSGs and 150 LRYGBs.
They work in our bariatric center of excellence that performs
over 1000 bariatric surgeries per year. The surgeons are
allowed to convert LSG into LRYGB and vice versa during
surgery by medical indication. Statistical analyses were car-
ried out according to the intention-to-treat principle.
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All patients who undergo bariatric surgery at our center are
treated according to a fast-track protocol and are discharged
1 day after surgery if no complications occur [37]. All patients
are also prescribed proton pump inhibitors (PPIs) for 6 weeks
after surgery. Postoperative follow-up occurs according to the
standard of care. Complications are scored at every consulta-
tion using the Clavien-Dindo classification [38].
Outcome Measures
The primary endpoint of this trial is QOL. Multiple question-
naires are filled out to evaluate QOL preoperatively and at
postoperative follow-up visits at 2 and 12 months. QOL relat-
ed to the gastrointestinal tract was assessed using the
Gastrointestinal Quality of Life Index (GIQLI), the Bariatric
Analysis and Reporting Outcome System (BAROS), and the
Gastroesophageal Reflux Disease Questionnaire (GerdQ)
[39–41]. The presence of asthma complaints was objectified
with the Asthma Control Questionnaire (ACQ) [42]. General
QOL was assessed using the EuroQol 5 Dimensions self-
report questionnaire (EQ-5D) and the Short Form (36)
Health Survey (SF-36) [43, 44]. Lastly, the Dutch Sweet
Eating Questionnaire (DSEQ) was used to evaluate the
amount of carbohydrates consumed [34].
Secondary endpoints in this trial were BMI and %EWL.
Since this trial was not powered to detect differences in
weight loss between the groups, these data will only be
used to assess if BMI and %EWL are associated with
changes in QOL.
Statistics
Data were analyzed using SPSS Statistics for Macintosh (ver-
sion 22.0; IBM, Armonk, NY). Values are reported as
mean ± SD or mean differences. Descriptive statistics were
used for demographics and presence of comorbidities. Scores
at each follow-up moment were compared within each group,
to assess improvement after surgery, by using Wilcoxon’s
signed rank test. Scores of each questionnaire were also com-
pared between groups at each follow-up moment by using the
Mann-Whitney U test. A two-tailed p value <0.05 was con-
sidered statistically significant.
Because our sample consists of a relatively small number
of patients, listwise deletion of cases with missing values
could soon lead to a decrease in statistical power. Therefore,
we created a copy of our dataset and used single imputation to
increase power and reduce potential bias. With single imputa-
tion, missing values were substituted by the median or mode
Fig. 1 Flowchart of patient inclusion and received treatment. LSG
laparoscopic sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric
bypass
Table 1 Baseline characteristics
LSG (n = 76) LRYGB (n = 74) p valuea
Age (mean ± SD) 45.5 (±11.2) 43.8 (±10.8) 0.334
Female sex 63 (82.9%) 61 (82.4%) 1.000
BMI (mean ± SD) 44.17 (±5.00) 44.03 (±5.28) (n = 73) 0.860
BMI >50 kg/m2 13 (17.1%) 13 (17.6%) 1.000
History of GERD 8 (10.5%) 14 (18.9%) 0.171
History of T2DM 19 (25.0%) 15 (20.3%) 0.560
History of hypertension 19 (25.0%) 13 (17.6%) 0.321
History of dyslipidemia 11 (14.5%) 14 (18.9%) 0.516
History of COPD 7 (9.2%) 0 (0.0%) 0.014*
History of OSAS 5 (6.6%) 9 (12.2%) 0.273
LSG laparoscopic sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric bypass, BMI body mass index,
GERD gastroesophageal reflux disease, T2DM type 2 diabetes mellitus, COPD chronic obstructive pulmonary
disease, OSAS obstructive sleep apnea syndrome
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
a Independent samples t test or Fisher’s exact test
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of that specific question in their respective group (LSG or
LRYGB). This was only done when less than a third of the
questions were missing. It has been shown that even when
substituting 30% of a questionnaire by the question’s mean,
median, or mode, a substantial level of agreement could be
achieved [45]. We then analyzed both the original dataset
and the dataset in which imputation was used to gener-
ate more cases.
Table 2 Differences in quality of
life before surgery, 2 months after
surgery, and 12 months after
surgery
LSG Number LRYGB Number p valuea
GerdQb
Baseline 6.17 (±1.53) 71 6.44 (±1.62) 68 0.421
2 months 6.95 (±2.14) 64 5.50 (±1.49) 62 <.001***
12 months 6.63 (±2.26) 63 5.60 (±1.07) 56 0.001***
BAROSc
Baseline 0.54 (±1.10) 76 0.56 (±1.18) 74 0.789
2 months 1.36 (±1.11) 72 1.35 (±1.02) 63 0.958
12 months 1.60 (±1.29) 68 1.82 (±0.98) 59 0.473
GIQLIc
Baseline 112.43 (±16.44) 75 110.69 (±17.51) 72 0.587
2 months 115.67 (±18.90) 71 113.84 (±18.45) 62 0.491
12 months 116.71 (±19.76) 69 118.41 (±14.69) 58 0.858
SF-36 Physical Healthc
Baseline 65.81 (±16.82) 75 61.09 (±19.58) 73 0.178
2 months 73.89 (±17.84) 71 74.68 (±16.68) 63 0.768
12 months 79.97 (±13.44) 69 79.33 (±13.12) 59 0.488
SF-36 Mental Healthc
Baseline 73.07 (±14.74) 75 69.14 (±18.85) 73 0.234
2 months 77.66 (±17.87) 71 79.88 (±14.77) 63 0.635
12 months 80.27 (±16.39) 69 79.65 (±15.78) 59 0.778
SF-36 Health Changec
Baseline 41.33 (±19.49) 75 46.92 (±23.55) 73 0.180
2 months 81.34 (±22.25) 71 81.35 (±21.05) 63 0.906
12 months 93.48 (±14.64) 69 90.25 (±20.24) 59 0.540
EQ-5Dc
Baseline 0.73 (±0.22) 75 0.75 (±0.23) 73 0.512
2 months 0.88 (±0.15) 71 0.87 (±0.18) 63 0.790
12 months 0.87 (±0.17) 69 0.87 (±0.16) 58 0.697
ACQb
Baseline 2.15 (±4.74) 74 1.67 (±3.49) 72 0.457
2 months 1.37 (±2.75) 71 0.98 (±3.11) 63 0.124
12 months 1.54 (±3.98) 68 0.71 (±2.07) 58 0.307
DSEQb
Baseline 18.72 (±5.13) 68 19.18 (±4.79) 68 0.417
2 months 16.64 (±4.63) 66 15.31 (±2.62) 58 0.430
12 months 18.45 (±4.63) 66 18.28 (±4.28) 57 0.935
All values are mean (±SD)
LSG laparoscopic sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric bypass, GerdQGastroesophageal
Reflux Disease Questionnaire, BAROS Bariatric Analysis and Reporting Outcome System, GIQLI
Gastrointestinal Quality of Life Index, SF-36 Short Form (36) Health Survey, EQ-5D EuroQol 5 Dimensions
self-report questionnaire, ACQ Asthma Control Questionnaire, DSEQ Dutch Sweet Eating Questionnaire
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
aMann-Whitney U test
b A lower score means an improvement in quality of life
c A higher score means an improvement in quality of life
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Results
Patient Characteristics
A total of 150 patients were included and randomized to either
LSG (76 patients) or LRYGB (74 patients). Figure 1 is a
flowchart showing the randomization as well as the actual
treatment. All patients who underwent surgery were seen after
1 year of follow-up; 128 had returned the 1-year follow-up
questionnaires at the time of analysis. Because of missing
data, the amount of patients of which any follow-up moment
was complete differed per questionnaire, ranging from 131 to
148 patients at baseline and 119 to 128 patients at 1-year
follow-up. By substituting missing values with the question’s
median or mode, we were able to add up to 15 extra cases per
questionnaire to be analyzed. Both the original data and the
substituted data were analyzed, and results did not differ sig-
nificantly before and after imputation.
Table 1 shows that characteristics of both groups were sim-
ilar at baseline, except that the LSG group contained signifi-
cantly more people with COPD.
Quality of Life
Comparisons of postoperative questionnaire scores between
the LSG group and the LRYGB group are shown in Table 2.
Two months after surgery, the mean GerdQ score was
6.95 ± 2.14 in the LSG group versus 5.50 ± 1.49 in the
LRYGB group (p < 0.001). After 1 year, the LSG group and
the LRYGB group had ameanGerdQ score of 6.63 ± 2.26 and
5.60 ± 1.07, respectively (p = 0.001). No other postoperative
questionnaires showed significant differences.
Table 3 shows the mean differences between baseline
scores and scores after 2 and after 12 months within each
group.Most QOL questionnaires showed significant improve-
ment in scores between baseline and after 12 months. The
GerdQ score deteriorated in the LSG group after 2 months,
but recovered after 1 year. Figure 2 is a graphical representa-
tion of the results shown in Tables 2 and 3.
Weight Loss and Complications
Table 4 shows BMI at baseline, after 2 months, and after
12 months (see also Fig. 3), as well as %EWL after 2 months
and after 12 months. It also includes the surgical complication
rate for the first year after surgery. There were no differences
in BMI or weight loss. The complication rate was 6.6% in
LSG and 10.8% in LRYGB (p = 0.398). Both groups had
one anastomotic leakage. There were two readmissions within
30 days in each group. There were no reported surgical site
infections, and there was no mortality.
Discussion
This trial has shown that patients after both LSG and LRYGB
had overall comparable improvement in QOL after 1 year of
follow-up. The only significant difference was that patients in
the LSG group had a higher mean GerdQ score after 1 year,
meaning they had more symptoms of GERD. A remarkable
finding was that people in the LSG group had increased
GerdQ scores after surgery, while patients in the LRYGB
Table 3 Improvement in quality of life over time
LSG p valuea LRYGB p valuea
GerdQb
Baseline vs 2 months 0.78 0.045* −0.94 <.001***
Baseline vs 12 months 0.46 0.132 −0.84 0.001***
BAROSc
Baseline vs 2 months 0.82 <.001*** 0.79 <.001***
Baseline vs 12 months 1.06 <.001*** 1.26 <.001***
GIQLIc
Baseline vs 2 months 3.24 0.039* 3.15 0.075
Baseline vs 12 months 4.28 0.012* 7.72 0.003**
SF-36 Physical Healthc
Baseline vs 2 months 8.08 <.001*** 13.59 <.001***
Baseline vs 12 months 14.16 <.001*** 18.24 <.001***
SF-36 Mental Healthc
Baseline vs 2 months 4.59 0.008** 10.74 <.001***
Baseline vs 12 months 7.20 <.001*** 10.51 <.001***
SF-36 Health Changec
Baseline vs 2 months 40.01 <.001*** 34.43 <.001***
Baseline vs 12 months 52.15 <.001*** 43.33 <.001***
EQ-5Dc
Baseline vs 2 months 0.15 <.001*** 0.12 <.001***
Baseline vs 12 months 0.14 <.001*** 0.12 <.001***
ACQb
Baseline vs 2 months −0.78 0.148 −0.69 0.014*
Baseline vs 12 months −0.61 0.105 −0.86 0.001***
DSEQb
Baseline vs 2 months −2.08 0.015* −3.87 <.001***
Baseline vs 12 months −0.27 0.753 −0.9 0.354
All values are mean differences
LSG Laparoscopic sleeve gastrectomy, LRYGB Laparoscopic Roux-en-Y
gastric bypass, GerdQ Gastroesophageal Reflux Disease Questionnaire,
BAROS Bariatric Analysis and Reporting Outcome System, GIQLI
Gastrointestinal Quality of Life Index, SF-36 Short Form (36) Health
Survey, EQ-5D EuroQol 5 Dimensions self-report questionnaire, ACQ
AsthmaControl Questionnaire,DSEQDutch Sweet Eating Questionnaire
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
aWilcoxon’s signed rank test
b A lower score means an improvement in quality of life
c A higher score means an improvement in quality of life
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group had significantly decreased GerdQ scores after surgery.
The%EWLwas equal in both groups, so it is unlikely that this
has influenced the difference in GERD symptoms.
In this trial, GERD was not objectified by pH monitoring,
the gold standard to diagnose GERD, nor by gastroscopy;
therefore, we can only rely on GerdQ scores. Despite the sig-
nificantly worse GerdQ scores in the LSG group, overall qual-
ity of life was not compromised, as shown by similar increases
in SF-36, EQ-5D, BAROS, and GIQLI scores in both groups.
This raises the question whether a slightly higher GerdQ score
is of clinical importance.
Other studies have described similar results regarding
GERD after LSG. One study concluded that LSG was associ-
ated with the development of GERD (diagnosed by using 24-h
pHmonitoring) in two thirds of patients who were asymptom-
atic before surgery [46]. Another study that also used pH
monitoring found that over 80% of previously asymptomatic
patients suffered from GERD 1 year after LSG [47]. A third
study diagnosed GERD using a combination of symptom
scoring and/or objective evidence such as contrast studies,
gastroscopy, and pH monitoring. They found that 3% of all
patients developed de novo GERD after LSG but that almost
all patients responded well to treatment with a PPI [48]. Other
studies that have used either symptom questionnaires or gas-
troscopy found similar results regarding the need for PPIs after
LSG [49, 50]. One more study found not only that 7% of
patients who were asymptomatic before surgery developed
de novo GERD after LSG but also that symptoms resolved
in 96% of patients who had GERD preoperatively [27].
Another study has found that patients with GERD after LSG
had a significantly higher rate of readmission within 30 days,
but the odds ratio for converting LSG into LRYGB was only
Fig. 2 a–i Improvement in quality of life over time. All values are mean,
whiskers show standard error of the mean (SEM). LSG laparoscopic
sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric bypass,
GerdQ Gastroesophageal Reflux Disease Questionnaire, BAROS
Bariatric Analysis and Reporting Outcome System, GIQLI
Gastrointestinal Quality of Life Index, SF-36 Short Form (36) Health
Survey, EQ-5D EuroQol 5 Dimensions self-report questionnaire, ACQ
AsthmaControl Questionnaire,DSEQDutch Sweet Eating Questionnaire
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higher in Caucasian patients [51]. Finally, the results of a
recently published randomized controlled trial comparing
LSG with LRYGB show that weight loss, quality of life, and
complications did not differ significantly after 3 years.
However, there was a slight difference in remission of
GERD in favor of the LRYGB group [52]. Another recent
systematic review and meta-analysis remained inconclusive
on the subject, stating the heterogeneity of recent publications
and their paradoxical outcomes [17]. Therefore, from the cur-
rently available literature, we can conclude that there is no
clear evidence that pre-existing GERD should be an absolute
contraindication for LSG.
Some studies have tried to come up with solutions to min-
imize GERD after LSG. A case series of 40 patients has
shown that 95% of patients with pre-existing GERD experi-
enced complete remission when anterior fundoplication with a
posterior crural approximation was added to LSG. During
stapling of the sleeve, a small fundus is left to use for anterior
fundoplication [53]. Another study used a similar technique of
fundoplication and called it the Nissen Sleeve (N-Sleeve),
after the Nissen fundoplication. They found that 88% of pa-
tients who had pre-existent esophageal syndromes had expe-
rienced remission 1 year after N-Sleeve [54].
The main limitation of the current trial is the small sample
size. Even though 150 patients seemed like a good sample
size, the analyses had to be done with substantially less data
because of patients skipping or forgetting questions from the
questionnaires. The authors tried to counter this by using me-
dian or mode imputation on the missing data. On top of the
missing questions, there were still some patients who had not
returned the 1-year follow-up questionnaires. Other limita-
tions include the lack of data on actual PPI usage and the lack
of esophageal pH monitoring for diagnosing GERD.
We recommend that further research should be focused on
the implications of GERD after LSG, rather than the mere
presence of symptoms. As this trial and some other studies
have already shown, a lot of patients did not suffer from these
symptoms and reported good quality of life on other validated
questionnaires. Also, the use of a PPI could be a simple solu-
tion to many patients with GERD symptoms. Future studies
should also evaluate other options to counter GERD after
LSG, like anterior fundoplication with posterior crural ap-
proximation or the N-Sleeve.
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Fig. 3 Body mass index over time. BMI body mass index, LSG
laparoscopic sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric
bypass
Table 4 Body mass index,
excess weight loss, and
complications
LSG Number LRYGB Number p valuea
BMI
Baseline 44.17 (±5.00) 76 44.03 (±5.28) 73 0.860
2 months 37.53 (±5.09) 72 39.45 (±1291) 66 0.261
12 months 30.77 (±5.70) 70 30.18 (±4.63) 60 0.516
%EWL
2 months 36.03 (±14.07) 72 33.16 (±9.45) 66 0.158
12 months 73.21 (±22.82) 70 75.60 (±21.02) 60 0.537
Complications 5 (6.6%) 76 8 (10.8%) 74 0.398
All values are mean (±SD)
LSG laparoscopic sleeve gastrectomy, LRYGB laparoscopic Roux-en-Y gastric bypass, BMI body mass index,
%EWL percentage excess weight loss
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
a Independent samples t test or Fisher’s exact test
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